Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Animal-health turnaround with Q1 2026 revenue up 15% YoY and guidance raised for revenue, adjusted EBITDA, adjusted EPS, innovation revenue, and net leverage; recent product launches/approvals and unusual options activity support near-term attention into 2026-08-05 earnings.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Recovery ⢠Strong Cash Flow ⢠Elevated Leverage ELAN's improving quarterly margins, positive free cash flow, and modest debt repayment support recovery potential, but high leverage, weak annual profitability, and intangible-heavy equity warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠August low rebound ⢠Short-term pullback ⢠Key range test Support Level: $23.55â$23.65 Resistance Level: $24.50 ELAN has recovered from its August low but is losing short-term momentum; watch $24.50 for a bullish breakout or $23.55 for downside risk.
Sentiment & News
Key News Insights: ⢠Raised Guidance ⢠Pet Health Growth ⢠Supply Constraints Elanco delivered strong Q2 growth and raised 2026 guidance, led by Pet Health launches, though shares fell on near-term supply concerns.
AI Summary
ELAN's improving outlook is now driven by measurable pet-health launch growth and operating leverage, but the investment hinges on whether Zenrelia and Credelio Quattro can convert into durable free cash flow that accelerates deleveraging below 3x rather than requiring sustained promotional spending.
Description
Elanco Animal Health Inc. develops, manufactures and markets pharmaceuticals, vaccines and nutritional health products for companion animals and food-producing species, including treatments for parasites, infectious disease and common chronic conditions. The company distributes through third-party distributors, veterinarians and farm producers across beef, dairy, pork, poultry and aquaculture markets; it was founded in 1954 and is headquartered in Greenfield, Indiana.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | ELAN | Elanco Animal Health Incorporated | Animal-health turnaround with Q1 2026 revenue up 15% YoY and guidance raised for revenue, adjusted EBITDA, adjusted EPS, innovation revenue, and net leverage; recent product launches/approvals and unusual options activity support near-term attention into 2026-08-05 earnings. | Closed | +0.2% |
| Jun 24 | Jul 1 | ELAN | Elanco Animal Health Incorporated | Multiple fresh animal-health catalysts: on 2026-05-06 Elanco raised full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; on 2026-06-15 USDA approved TruCan Ultra Lyme-L4 with shipping expected within 30 days; Q1 2026 margins and profitability improved, supporting a constructive short-term setup. | Closed | +0.5% |
| Jun 12 | Jun 19 | ELAN | Elanco Animal Health Incorporated | Animal-health guidance raise with product catalysts: Q1 2026 revenue grew 15% YoY to $1.371B, management raised 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and innovation revenue, while new launches such as Advantage Collar for Dogs and Befrena support near-term sentiment. Stock is up about 12% over 21 trading days. | Closed | +0.2% |
| Jun 5 | Jun 12 | ELAN | Elanco Animal Health Incorporated | Animal-health recovery with concrete catalysts: Q1 2026 revenue grew 15% YoY to $1.371B and management raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and year-end leverage. New products including Befrena and Advantage Collar plus the New World screwworm backdrop add timely sector support. | Closed | +2.3% |